Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in clinical practice Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

ESC 365 is supported by

ESC 365 is supported by